Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.
2.

Using PARP Inhibitors in Advanced Ovarian Cancer.

O'Cearbhaill RE.

Oncology (Williston Park). 2018 Jul 15;32(7):339-43.

3.

Development of poly(ADP-ribose) polymerase inhibitors in the treatment of BRCA-mutated breast cancer.

Sulai NH, Tan AR.

Clin Adv Hematol Oncol. 2018 Jul;16(7):491-501. Review.

PMID:
30067621
4.

PARP inhibitors for ovarian cancer.

[No authors listed]

Med Lett Drugs Ther. 2017 Dec 4;59(1535):200-202. No abstract available.

PMID:
29186085
5.

Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.

Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, McNeish IA, Swisher EM, Ray-Coquard I, Bell-McGuinn K, Coleman RL, O'Malley DM, Leary A, Chen LM, Provencher D, Ma L, Brenton JD, Konecny GE, Castro CM, Giordano H, Maloney L, Goble S, Lin KK, Sun J, Raponi M, Rolfe L, Kristeleit RS.

Gynecol Oncol. 2017 Nov;147(2):267-275. doi: 10.1016/j.ygyno.2017.08.022. Epub 2017 Sep 4.

6.

Targeted therapy of ovarian cancer including immune check point inhibitor.

Kim JY, Cho CH, Song HS.

Korean J Intern Med. 2017 Sep;32(5):798-804. doi: 10.3904/kjim.2017.008. Epub 2017 Aug 22. Review.

7.

Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas.

Laroche A, Chaire V, Le Loarer F, Algéo MP, Rey C, Tran K, Lucchesi C, Italiano A.

J Hematol Oncol. 2017 Apr 11;10(1):84. doi: 10.1186/s13045-017-0451-x.

8.

New treatment for patients with advanced ovarian cancer receives accelerated approval.

Printz C.

Cancer. 2017 Apr 15;123(8):1286-1287. doi: 10.1002/cncr.30714. No abstract available.

9.

A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors.

Kristeleit R, Shapiro GI, Burris HA, Oza AM, LoRusso P, Patel MR, Domchek SM, Balmaña J, Drew Y, Chen LM, Safra T, Montes A, Giordano H, Maloney L, Goble S, Isaacson J, Xiao J, Borrow J, Rolfe L, Shapira-Frommer R.

Clin Cancer Res. 2017 Aug 1;23(15):4095-4106. doi: 10.1158/1078-0432.CCR-16-2796. Epub 2017 Mar 6.

10.

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.

Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, Konecny GE, Coleman RL, Tinker AV, O'Malley DM, Kristeleit RS, Ma L, Bell-McGuinn KM, Brenton JD, Cragun JM, Oaknin A, Ray-Coquard I, Harrell MI, Mann E, Kaufmann SH, Floquet A, Leary A, Harding TC, Goble S, Maloney L, Isaacson J, Allen AR, Rolfe L, Yelensky R, Raponi M, McNeish IA.

Lancet Oncol. 2017 Jan;18(1):75-87. doi: 10.1016/S1470-2045(16)30559-9. Epub 2016 Nov 29.

11.

The current status of PARP inhibitors in ovarian cancer.

McLachlan J, George A, Banerjee S.

Tumori. 2016 Oct 13;102(5):433-440. doi: 10.5301/tj.5000558. Epub 2016 Sep 24. Review.

PMID:
27716873
12.

PARP activity in peripheral blood lymphocytes as a predictive biomarker for PARP inhibition in tumor tissues - A population pharmacokinetic/pharmacodynamic analysis of rucaparib.

Wang DD, Li C, Sun W, Zhang S, Shalinsky DR, Kern KA, Curtin NJ, Sam WJ, Kirkpatrick TR, Plummer R.

Clin Pharmacol Drug Dev. 2015 Mar;4(2):89-98. doi: 10.1002/cpdd.176. Epub 2015 Jan 26.

PMID:
27128213
13.

Clinical Trials of Poly(ADP-Ribose) Polymerase Inhibitors for Cancer Therapy: A Review.

Buege M, Mahajan PB.

Rev Recent Clin Trials. 2015;10(4):326-39. Review.

PMID:
26374559
14.

A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation.

Plummer R, Lorigan P, Steven N, Scott L, Middleton MR, Wilson RH, Mulligan E, Curtin N, Wang D, Dewji R, Abbattista A, Gallo J, Calvert H.

Cancer Chemother Pharmacol. 2013 May;71(5):1191-9. doi: 10.1007/s00280-013-2113-1. Epub 2013 Feb 20.

PMID:
23423489
15.

The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice.

Ali M, Kamjoo M, Thomas HD, Kyle S, Pavlovska I, Babur M, Telfer BA, Curtin NJ, Williams KJ.

Mol Cancer Ther. 2011 Dec;10(12):2320-9. doi: 10.1158/1535-7163.MCT-11-0356. Epub 2011 Sep 16.

16.

Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.

Plummer R, Jones C, Middleton M, Wilson R, Evans J, Olsen A, Curtin N, Boddy A, McHugh P, Newell D, Harris A, Johnson P, Steinfeldt H, Dewji R, Wang D, Robson L, Calvert H.

Clin Cancer Res. 2008 Dec 1;14(23):7917-23. doi: 10.1158/1078-0432.CCR-08-1223.

Supplemental Content

Loading ...
Support Center